profit from every $100 of sales.
$0$100
Caris Life Sciences
$23.04-3.84% today
-3.0% in 1 year
1-year low $14.551-year high $36.14
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Caris Life Sciences sold, what it kept, and what it did with the cash.
Sales went from $258 million in 2022 to $812 million in 2025, with -$68.1 million of profit last year.
SalesProfit
Caris Life Sciences handed back 0% of the cash it generated last year.
Buybacks $113,000
Free cash flow 2025$67M
Bought back its own shares$113,000
Paid as dividends–
Cash vs. debt$796M vs. $428M
Caris Life Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Caris Life Sciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Caris Life Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 258 | 306 | 412 | 812 | |
| 80 | 89 | 179 | 539 | |
| -316 | -320 | -257 | 45 | |
| -246 | -261 | -183 | 11 | |
| -321 | -341 | -282 | -68 | |
| -1.57 | -1.82 | -1.36 | -3.22 | |
| 31.0% | 29.2% | 43.4% | 66.4% | |
| -122.2% | -104.4% | -62.4% | 5.6% | |
| -124.1% | -111.5% | -68.4% | -8.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 717 | 413 | 344 | 1,126 |
| Cash | 107 | 56 | 64 | 796 |
| Total debt | 271 | 217 | 424 | 428 |
| Total liabilities | 2,420 | 2,558 | 2,843 | 548 |
| -1,702 | -2,145 | -2,499 | 577 | |
| 255 | 255 | 278 | 167 | |
| – | – | – | -0.9% | |
| 18.8% | 15.9% | 11.3% | -11.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -286 | -276 | -245 | 83 | |
| 42 | 22 | 8 | 16 | |
| -328 | -298 | -254 | 67 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 0 | |
| 23 | 15 | 19 | 70 |
Valuation
- –
- 192.4×
- –
- 11.4×
- 8.1×
- 98.8×
- 548.2×
- 1.0%
- -1.0%
- 0.0%
Profitability
- 66.4%
- 5.6%
- -8.4%
- 11.5%
- -0.9%
- -0.9%
- 6.5%
- 2.9%
- 14.2%
- 9.2%
Growth
- +46.5%
- –
- +126.4%
- –
- −13.1%
Financial health
- -32.4×
- 0.74
- 0.0%
- -0.2×
- 7.85
- 7.05
- 0.78
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 35%of 946
Bottom 42%of 871
Top 13%of 867
Bottom 49%of 986
What analysts expect
- Average price target
- $28.75
- Range
- $21.00 – $38.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.00 | -0.02 | +92.5% |
| Feb 26, 2026 | 0.28 | -0.02 | +1,500.0% |
| Nov 5, 2025 | 0.08 | -0.08 | +200.0% |
| Aug 12, 2025 | -0.54 | -0.21 | −157.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
40No pass
Philip Fisher
47No pass
Peter Lynch
71Pass
Joel Greenblatt
14No pass
Charlie Munger
33No pass
Terry Smith
35No pass
Questions about Caris Life Sciences
Is Caris Life Sciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Caris Life Sciences AI analysis
What does Caris Life Sciences do?
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It is in Biotechnology, based in Irving, TX, United States, with 1,846 employees.
Does Caris Life Sciences pay a dividend?
No. Caris Life Sciences does not pay a dividend at the moment; in 2025 it returned $113,000 to shareholders by buying back its own shares.
Is Caris Life Sciences stock halal?
Yes. Caris Life Sciences passes our halal screen: its business is permitted and its debt is 6% of its market value, under the 30% limit. How we check
How has Caris Life Sciences stock done over the past year?
Down 3.0% over the past twelve months, to $23.04. It traded between $14.55 and $36.14 and is 36.2% below its high.
Who are Caris Life Sciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Caris Life Sciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.